NEXI-002 is an autologous T cell therapy that generates cytotoxic T cells directed against multiple tumor antigens. These antigens include WT1, CD138, CS1 and NY-ESO-1.
SparkCures ID | 350 |
---|---|
Developed By | NexImmune |
Generic Name | NEXI-002 |
Treatment Classifications |
|
Treatment Targets |
|